ISARIC Global Support Centre, Centre for Tropical Medicine and Global Heatlh, University of Oxford, Oxford, UK
Infection and Global Health Division, School of Medicine, University of St Andrews, St Andrews, UK.
BMJ Open. 2021 Mar 10;11(3):e043887. doi: 10.1136/bmjopen-2020-043887.
Very little is known about possible clinical sequelae that may persist after resolution of acute COVID-19. A recent longitudinal cohort from Italy including 143 patients followed up after hospitalisation with COVID-19 reported that 87% had at least one ongoing symptom at 60-day follow-up. Early indications suggest that patients with COVID-19 may need even more psychological support than typical intensive care unit patients. The assessment of risk factors for longer term consequences requires a longitudinal study linked to data on pre-existing conditions and care received during the acute phase of illness. The primary aim of this study is to characterise physical and psychosocial sequelae in patients post-COVID-19 hospital discharge.
This is an international open-access prospective, observational multisite study. This protocol is linked with the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) and the WHO's Clinical Characterisation Protocol, which includes patients with suspected or confirmed COVID-19 during hospitalisation. This protocol will follow-up a subset of patients with confirmed COVID-19 using standardised surveys to measure longer term physical and psychosocial sequelae. The data will be linked with the acute phase data. Statistical analyses will be undertaken to characterise groups most likely to be affected by sequelae of COVID-19. The open-access follow-up survey can be used as a data collection tool by other follow-up studies, to facilitate data harmonisation and to identify subsets of patients for further in-depth follow-up. The outcomes of this study will inform strategies to prevent long-term consequences; inform clinical management, interventional studies, rehabilitation and public health management to reduce overall morbidity; and improve long-term outcomes of COVID-19.
The protocol and survey are open access to enable low-resourced sites to join the study to facilitate global standardised, longitudinal data collection. Ethical approval has been given by sites in Colombia, Ghana, Italy, Norway, Russia, the UK and South Africa. New sites are welcome to join this collaborative study at any time. Sites interested in adopting the protocol as it is or in an adapted version are responsible for ensuring that local sponsorship and ethical approvals in place as appropriate. The tools are available on the ISARIC website (www.isaric.org). PROTOCOL REGISTRATION NUMBER: osf.io/c5rw3/ PROTOCOL VERSION: 3 August 2020 EUROQOL ID: 37035.
关于急性 COVID-19 痊愈后可能持续存在的临床后遗症,我们知之甚少。最近,意大利的一项包含 143 名住院 COVID-19 患者的纵向队列研究报告称,60 天随访时,87%的患者至少存在一种持续症状。早期迹象表明,COVID-19 患者可能比典型的重症监护病房患者更需要心理支持。评估长期后果的危险因素需要进行一项纵向研究,该研究与疾病急性期的预先存在的疾病状况和所接受的护理数据相关联。本研究的主要目的是描述 COVID-19 出院后患者的身体和心理社会后遗症。
这是一项国际性的、开放获取的、前瞻性的、观察性的多地点研究。本方案与国际严重急性呼吸和新兴感染联合会(ISARIC)以及世界卫生组织的临床特征化方案相关联,该方案包括住院期间疑似或确诊 COVID-19 的患者。本方案将使用标准化调查对确诊 COVID-19 的患者进行随访,以测量长期的身体和心理社会后遗症。数据将与急性期数据相关联。将进行统计分析,以确定最有可能受 COVID-19 后遗症影响的人群。开放获取的随访调查可作为其他随访研究的数据收集工具,以促进数据协调,并确定进一步深入随访的患者亚组。该研究的结果将为预防长期后果的策略提供信息;为临床管理、干预研究、康复和公共卫生管理提供信息,以降低整体发病率;并改善 COVID-19 的长期结果。
该方案和调查是开放获取的,以使资源较少的地点能够加入该研究,从而促进全球标准化的纵向数据收集。该方案已获得哥伦比亚、加纳、意大利、挪威、俄罗斯、英国和南非的站点批准。欢迎新的站点随时加入这项合作研究。有兴趣采用该方案或改编版本的站点负责确保适当的当地赞助和伦理批准。该工具可在 ISARIC 网站(www.isaric.org)上获取。方案注册号:osf.io/c5rw3/ 方案版本:2020 年 8 月 3 日。欧洲生活质量五维量表(EQ-5D)编号:37035。